63968-74-1

Basic information

• Product Name: (2E)-4-Methoxy-2-butenoic Acid
• Synonyms: (2E)-4-Methoxy-2-butenoic Acid;2-Butenoicacid,4-Methoxy-,(E)-;ZOJKRWXDNYZASL-NSCUHMNNSA-N
• CAS NO: 63968-74-1
• Molecular Formula: C₅H₈O₃
• Molecular Weight: 116.11522
• Product Categories: Miscellaneous Reagents
• Mol File: 63968-74-1.mol
• Article Data: 8

Chemical Properties

• Melting Point: 66-67 °C
• Boiling Point: 248.3±23.0 °C(Predicted)
• Appearance: /
• Density: 1.098±0.06 g/cm3(Predicted)
• Storage Temp.: Refrigerator, under inert atmosphere
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 4.37±0.10(Predicted)
• CAS DataBase Reference: (2E)-4-Methoxy-2-butenoic Acid(CAS DataBase Reference)
• NIST Chemistry Reference: (2E)-4-Methoxy-2-butenoic Acid(63968-74-1)
• EPA Substance Registry System: (2E)-4-Methoxy-2-butenoic Acid(63968-74-1)

Safety Data

• Hazardous Substances Data: 63968-74-1(Hazardous Substances Data)

Usage

Description

(2E)-4-Methoxy-2-butenoic Acid is an organic compound characterized by the presence of a 2-butenoic acid backbone with a methoxy group at the 4-position and a trans double bond. It is known for its ability to form esters with hydroxy groups in molecules, providing protection during chemical reactions.

Uses

Used in Chemical Synthesis:
(2E)-4-Methoxy-2-butenoic Acid is used as a protecting group for hydroxy groups in molecules during chemical synthesis. It forms esters such as cronate, which protect the hydroxy groups from unwanted reactions, allowing for selective reactions to occur at other sites in the molecule.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, (2E)-4-Methoxy-2-butenoic Acid is used as a key intermediate in the synthesis of various drugs and drug candidates. Its ability to protect hydroxy groups makes it a valuable tool in the development of complex organic molecules with specific biological activities.
Used in Organic Chemistry Research:
(2E)-4-Methoxy-2-butenoic Acid is also utilized in organic chemistry research for the study of ester formation, protection strategies, and the development of new synthetic methodologies. Its unique properties make it a versatile compound for exploring new reaction pathways and mechanisms.

Upstream product

• 13991-36-1 4-bromocrotonic acid 
• 1117-71-1 methyl-4-bromo-2-butenoate 
• 13991-36-1 4-bromocrotonic acid 
• 124-41-4 sodium methylate 
• 67-56-1 methanol 

Downstream Products

• 13168-99-5 methyl 4-methoxy-trans-crotonate 
• 10035-10-6 hydrogen bromide 
• 1609467-13-1 5-amino-3-[4-(2,4-difluorophenoxy)phenyl]-1-{(3R)-1-[(2E)-4-methoxybut-2-enoyl]piperidin-3-yl}-1H-pyrazole-4-carboxamide 
• 1319717-91-3 (4R)-3-[(3S)-4-methoxy-3-methylbutanoyl]-4-phenyl-1,3-oxazolidin-2-one 
• 1319717-83-3 (4R)-3-[(2R)-2-[(2S)-1-methoxypropan-2-yl]pent-4-enoyl]-4-phenyl-1,3-oxazolidin-2-one 

Relevant articles and documents

QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITOR, COMPOSITIONS, METHODS OF MAKING THEM AND THEIR USE

The present disclosure relates to new compounds or pharmaceutically acceptable salts or stereoisomers thereof of formula I as inhibitors of receptor tyrosine kinases (RTK), in particular extracellular mutants of ErbB-receptors. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the treatment of cancer in mammals (e.g. humans).

ALKYNYL-SUBSTITUTED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF

The present invention relates to an alkynyl-substituted heterocyclic compound acting as an FGFR inhibitor, a preparation method therefor and a medical use thereof. In particular, the present invention relates to a compound as shown in general formula (I) and a pharmaceutically acceptable salt thereof; a pharmaceutical composition including the compound or a pharmaceutically acceptable salt thereof; a method for treating and/or preventing FGFR-associated diseases, particularly tumors, by using the compound or a pharmaceutically acceptable salt thereof; and a preparation method for the compound or a pharmaceutically acceptable salt thereof. The present invention also relates to the use of the compound or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition including the compound or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating and/or preventing FGFR-associated diseases, particularly tumors, wherein the definition of each substituent group in general formula (I) is the same as that in the description.

Syn-effect' in the diastereoselective alkylation of 3-[(E)-α,β-unsaturated-γ-substituted]-N-acyloxazolidinones

Synthetic methods for the formation of alkenes usually produce the E-alkene because it is more stable. However, in isomerization reaction (double bond migration) that takes place in α, β-unsaturated carbonyl compounds, when these carbonyl compounds are exposed to strong bases, furnish Z-alkenes highly stereoselective depending on the γ-substituent in the α, β-unsaturated carbonyl. This stereoselectivity can be attributed to the known Syn-effect. The synthetic value of this methodology is the achievement of chiral alcohol bearing an electron rich Z-alkene, as well as substituted, which was accomplished via removal of the oxazolidinone moiety under treatment with NaBH4, THF-H2O.